US Bancorp DE Cuts Position in Inari Medical, Inc. (NASDAQ:NARI)

US Bancorp DE trimmed its holdings in Inari Medical, Inc. (NASDAQ:NARI) by 19.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,279 shares of the company’s stock after selling 314 shares during the period. US Bancorp DE’s holdings in Inari Medical were worth $53,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NARI. Bamco Inc. NY boosted its stake in Inari Medical by 27.4% in the 1st quarter. Bamco Inc. NY now owns 777,152 shares of the company’s stock worth $37,288,000 after buying an additional 167,000 shares during the last quarter. Lighthouse Investment Partners LLC bought a new stake in shares of Inari Medical in the second quarter worth $2,145,000. Integral Health Asset Management LLC boosted its stake in Inari Medical by 100.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company’s stock valued at $19,260,000 after acquiring an additional 200,000 shares during the last quarter. Seven Eight Capital LP bought a new position in Inari Medical during the 1st quarter valued at $499,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Inari Medical by 1,219.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 394,901 shares of the company’s stock worth $19,014,000 after acquiring an additional 364,983 shares in the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. William Blair assumed coverage on shares of Inari Medical in a research report on Thursday, July 25th. They set an “outperform” rating for the company. Wells Fargo & Company cut their price objective on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Robert W. Baird lifted their target price on Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday, October 29th. Finally, Canaccord Genuity Group increased their price target on Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a research note on Tuesday, October 29th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Inari Medical presently has an average rating of “Hold” and a consensus price target of $58.89.

Insider Transactions at Inari Medical

In other news, CFO Mitch C. Hill sold 3,000 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total value of $135,390.00. Following the transaction, the chief financial officer now directly owns 179,600 shares of the company’s stock, valued at approximately $8,105,348. This represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction on Monday, September 16th. The shares were sold at an average price of $45.83, for a total value of $1,833,200.00. Following the sale, the director now directly owns 643,296 shares of the company’s stock, valued at approximately $29,482,255.68. The trade was a 5.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 126,000 shares of company stock valued at $5,921,390 over the last quarter. Company insiders own 10.60% of the company’s stock.

Inari Medical Trading Up 2.7 %

NARI stock opened at $50.56 on Monday. The firm has a 50-day moving average of $45.19 and a two-hundred day moving average of $47.05. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $67.13. The firm has a market capitalization of $2.96 billion, a PE ratio of -37.45 and a beta of 0.96.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.